Episode 65 - Robert Ross - CEO of Clasp Therapeutics
Description
We were delighted to welcome Robert Ross, Chief Executive Officer at Clasp Therapeutics, onto The BioHub. Clasp Therapeutics are a pioneering biotech company spearheading the next generation of T-cell engager therapies. Founded in 2024 and backed by a successful $150 million Series A round with top tier investors, Clasp stands out for its novel approach in delivering off-the-shelf, bispecific T‐cell engagers that narrowly target cancer-driving mutations while sparing healthy tissues. Dr. Ross brings a wealth of experience to Clasp’s mission. Before stepping into the CEO role at Clasp in November 2023, he led Surface Oncology through its acquisition by Coherus Biosciences and directed oncology strategy at bluebird bio, where he played a key role in advancing groundbreaking CAR T-cell therapies.In this episode we dive into inspiration behind the founding of Clasp, what it takes to build a biotech and the shift from preclinical to clinical, an insight into some of the work Clasp are doing, as well as Rob transitioning from a practicing Oncologist to a Biotech CEO.
United States
